IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v40y2022i2d10.1007_s40273-022-01226-7.html
   My bibliography  Save this article

EQ-5D-Y-3L Value Sets, Valuation Methods and Conceptual Questions

Author

Listed:
  • Nancy Devlin

    (University of Melbourne)

  • Bram Roudijk

    (CHERE, University of Technology Sydney)

  • Rosalie Viney

    (EuroQol Research Foundation)

  • Elly Stolk

    (CHERE, University of Technology Sydney)

Abstract

No abstract is available for this item.

Suggested Citation

  • Nancy Devlin & Bram Roudijk & Rosalie Viney & Elly Stolk, 2022. "EQ-5D-Y-3L Value Sets, Valuation Methods and Conceptual Questions," PharmacoEconomics, Springer, vol. 40(2), pages 123-127, December.
    • Handle: RePEc:spr:pharme:v:40:y:2022:i:2:d:10.1007_s40273-022-01226-7
    DOI: 10.1007/s40273-022-01226-7
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-022-01226-7
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40273-022-01226-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. David J. Mott & Nancy J. Devlin & Simone Kreimeier & Richard Norman & Koonal K. Shah & Oliver Rivero-Arias, 2022. "Analytical Considerations When Anchoring Discrete Choice Experiment Values Using Composite Time Trade-Off Data: The Case of EQ-5D-Y-3L," PharmacoEconomics, Springer, vol. 40(2), pages 129-137, December.
    2. Valentina Prevolnik Rupel & Marko Ogorevc, 2021. "EQ-5D-Y Value Set for Slovenia," PharmacoEconomics, Springer, vol. 39(4), pages 463-471, April.
    3. Jonathan L. Nazari & A. Simon Pickard & Ning Yan Gu, 2022. "Findings from a Roundtable Discussion with US Stakeholders on Valuation of the EQ-5D-Y-3L," PharmacoEconomics, Springer, vol. 40(2), pages 139-146, December.
    4. Titi Sahidah Fitriana & Bram Roudijk & Fredrick Dermawan Purba & Jan J. V. Busschbach & Elly Stolk, 2022. "Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values," PharmacoEconomics, Springer, vol. 40(2), pages 157-167, December.
    5. Fanni Rencz & Gábor Ruzsa & Alex Bató & Zhihao Yang & Aureliano Paolo Finch & Valentin Brodszky, 2022. "Value Set for the EQ-5D-Y-3L in Hungary," PharmacoEconomics, Springer, vol. 40(2), pages 205-215, December.
    6. Sarah Dewilde & Bram Roudijk & Nafthali H. Tollenaar & Juan M. Ramos-Goñi, 2022. "An EQ-5D-Y-3L Value Set for Belgium," PharmacoEconomics, Springer, vol. 40(2), pages 169-180, December.
    7. S. A. Lipman & V. T. Reckers-Droog & M. Karimi & M. Jakubczyk & A. E. Attema, 2021. "Self vs. other, child vs. adult. An experimental comparison of valuation perspectives for valuation of EQ-5D-Y-3L health states," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(9), pages 1507-1518, December.
    8. Bram Roudijk & Ayesha Sajjad & Brigitte Essers & Stefan Lipman & Peep Stalmeier & Aureliano Paolo Finch, 2022. "A Value Set for the EQ-5D-Y-3L in the Netherlands," PharmacoEconomics, Springer, vol. 40(2), pages 193-203, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Zhihao Yang & Jie Jiang & Pei Wang & Xuejing Jin & Jing Wu & Yu Fang & Da Feng & Xiaoyu Xi & Shunping Li & Mingxia Jing & Bin Zheng & Weidong Huang & Nan Luo, 2022. "Estimating an EQ-5D-Y-3L Value Set for China," PharmacoEconomics, Springer, vol. 40(2), pages 147-155, December.
    2. Jonathan L. Nazari & A. Simon Pickard & Ning Yan Gu, 2022. "Findings from a Roundtable Discussion with US Stakeholders on Valuation of the EQ-5D-Y-3L," PharmacoEconomics, Springer, vol. 40(2), pages 139-146, December.
    3. David J. Mott & Nancy J. Devlin & Simone Kreimeier & Richard Norman & Koonal K. Shah & Oliver Rivero-Arias, 2022. "Analytical Considerations When Anchoring Discrete Choice Experiment Values Using Composite Time Trade-Off Data: The Case of EQ-5D-Y-3L," PharmacoEconomics, Springer, vol. 40(2), pages 129-137, December.
    4. Sarah Dewilde & Bram Roudijk & Nafthali H. Tollenaar & Juan M. Ramos-Goñi, 2022. "An EQ-5D-Y-3L Value Set for Belgium," PharmacoEconomics, Springer, vol. 40(2), pages 169-180, December.
    5. Stefan A. Lipman & Liying Zhang & Koonal K. Shah & Arthur E. Attema, 2023. "Time and lexicographic preferences in the valuation of EQ-5D-Y with time trade-off methodology," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(2), pages 293-305, March.
    6. Jiaer Lin & Carlos King Ho Wong & Jason Pui Yin Cheung & Prudence Wing Hang Cheung & Nan Luo, 2022. "Psychometric performance of proxy-reported EQ-5D youth version 5-level (EQ-5D-Y-5L) in comparison with three-level (EQ-5D-Y-3L) in children and adolescents with scoliosis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(8), pages 1383-1395, November.
    7. Takeru Shiroiwa & Takashi Fukuda, 2021. "EQ-5D-Y Population Norms for Japanese Children and Adolescents," PharmacoEconomics, Springer, vol. 39(11), pages 1299-1308, November.
    8. Stefan A. Lipman & Liying Zhang & Koonal K. Shah & Arthur E. Attema, 2022. "Correction to: Time and lexicographic preferences in the valuation of EQ-5D-Y with time trade-off methodology," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(9), pages 1613-1615, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:40:y:2022:i:2:d:10.1007_s40273-022-01226-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.